IDEAYA Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Trading Plans
During the three months ended December 31, 2025, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Name and Title | Action | Adoption Date | Termination Date | Trading Arrangement | Total Shares to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5‑1** | |||||
| Yujiro S. HataPresident and Chief Executive Officer | Adopt & Terminate | November 12, 2025 | December 11, 2025 | X | 330,316 | August 10, 2026 |
| Andres Ruiz BrisenoChief Accounting Officer | Adopt | December 19, 2025 | X | 28,150 | December 15, 2026 | |
* Intended to satisfy the affirmative defense of Rule 10b5-1(c)** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.